-
1 week ago | 
ajmc.com | Pieter Sonneveld |Mary Caffrey |Rose McNulty
The PERSEUS (NCT03710603) and CEPHEUS (NCT03652064) trials both demonstrated improved depth and duration of responses and progression-free survival (PFS) with a quadruplet regimen of daratumumab plus bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) in patients with multiple myeloma.1,2 Although these trials support the use of frontline daratumumab plus VRd in both transplant-eligible and transplant-ineligible patients, the median PFS for patients in these studies is...
-
1 week ago | 
ajmc.com | Mary Caffrey
Successfully targeting KRASG12C has been one of the major achievements of the decade in cancer care.
-
1 week ago | 
ajmc.com | Mary Caffrey
Data exploring a new type of tumor-fighting vaccine, presented last week at the American Association for Cancer Research (AACR), hint at game-changing news that could come by the end of the year.
-
2 weeks ago | 
ajmc.com | Mary Caffrey
Use of testing to detect and diagnose cancer, and then guide treatment decisions, is an essential part of precision medicine in oncology. Unfortunately, testing in oncology is below optimal levels, in part because of inconsistent payer coverage. Biomarker testing to find actionable mutations may be limited to fewer genes than an oncologist desires, or results may not be properly interpreted.
-
2 weeks ago | 
ajmc.com | Mary Caffrey
Women who survive cancer are 69% more likely to experience cancer-related fatigue and 58% more likely to suffer depression than men, according to an analysis of responses to a national health survey presented Tuesday at the American Association for Cancer Research (AACR) Annual Meeting in Chicago.1 Simo Du, MD, MHS, a resident at NYC Health + Hospitals/Jacobi and Albert Einstein College of Medicine, led a team that evaluated responses to 2 cycles of the National Health and Nutrition...
-
2 weeks ago | 
ajmc.com | Mary Caffrey
More so than most cancer meetings, scientific presentations at the American Association for Cancer Research (AACR) often are a glimpse into the future. Here, the floor belongs to basic science, as well as “first in human” and “proof of concept” phase 1 trials that shed light on brand new treatment approaches. Below are a sampling of early stage newsmakers from this year’s meeting, held April 25-30, 2025, in Chicago, Illinois.
-
2 weeks ago | 
ajmc.com | Mary Caffrey |Brooke McCormick
Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2-mutated non–small cell lung cancer (NSCLC), yielded durable responses with a highly manageable safety profile in results presented Monday at the American Association for Cancer Research (AACR) annual meeting in Chicago.1 The study, Beamion LUNG-1, simultaneously appeared in the New England Journal of Medicine (NEJM).2 “It's very exciting for the first time to have an oral drug where the...
-
2 weeks ago | 
ajmc.com | Mary Caffrey
A panel of scientists, policy leaders, and advocates on Sunday called for the cancer research community to push back against the “destabilizing” actions of the Trump administration, which they warn is dismantling the nation’s research infrastructure, putting careers of a generation of scientists in jeopardy, and threatening patients’ lives.
-
2 weeks ago | 
ajmc.com | Mary Caffrey
Patients with multiple types of locally advanced, mismatch repair-deficient (dMMR) tumors were able to avoid surgery following treatment with the PD-1 inhibitor dostarlimab (Jemperli, GSK) according to updated data being presented today at the American Association for Cancer Research (AACR) annual meeting in Chicago.1 Results, presented by Andrea Cercek, MD, attending and section head of colorectal cancer at Memorial Sloan Kettering (MSK) Cancer Center, could boost confidence in a nonsurgical...
-
3 weeks ago | 
ajmc.com | Mary Caffrey
This week, New York Oncology Hematology (NYOH), a 30-year-old cancer care practice in the Albany, New York, region, announced it would become part of OneOncology, the Nashville-based managed services organization (MSO) founded in 2018. NYOH is a physician-owned oncology practice with 60 providers, including 35 physicians, who treat patients at clinics in Albany, Amsterdam, Clifton Park, Hudson, and Troy, New York.
